Tirzepatide vs Retatrutide
Side-by-side literature comparison of a dual GLP-1 / GIP receptor agonist (Tirzepatide) and a triple GLP-1 / GIP / glucagon receptor agonist (Retatrutide) at the receptor-pharmacology level.
Side-by-Side Attributes
Objective data pulled from the published peptide literature. For research context only — not efficacy or performance claims.
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Class | Dual GLP-1 / GIP receptor agonist | Triple GLP-1 / GIP / glucagon receptor agonist |
| Receptor targets | GLP-1R + GIPR | GLP-1R + GIPR + GCGR |
| Length | 39 amino acids | 39 amino acids |
| Molecular Weight | ~4813.5 Da | ~4731 Da |
| Lipid modification | C20 fatty diacid on Lys20 | C20 fatty diacid side chain |
| Parent sequence lineage | Chimeric backbone drawing on GIP + GLP-1 features | Chimeric backbone drawing on GLP-1, GIP, and glucagon |
| First described (public literature) | ~2018 | ~2022 |
| Additional receptor engaged (vs dual) | — | GCGR (glucagon receptor) |
| In-vitro half-life (preclinical model reports) | Reported extended vs native GLP-1 and GIP | Reported extended vs native peptides across all three receptor families |
| Synthesis complexity | SPPS with orthogonal protection + on-resin lipidation | SPPS with orthogonal protection + on-resin lipidation |
| Endotoxin release spec (BioInfinity) | < 0.5 EU/mg by LAL | < 0.5 EU/mg by LAL |
| Third-party COA lab (BioInfinity) | Verum Analytics, Switzerland | Verum Analytics, Switzerland |
Literature Context
Tirzepatide (2018) and Retatrutide (2022) are two Eli Lilly engineered incretin-family research peptides that share a chimeric backbone strategy but differ in receptor breadth. Tirzepatide engages two receptors — GLP-1R and GIPR. Retatrutide adds a third — the glucagon receptor (GCGR) — to that dual profile.
From a structural standpoint the two peptides are similar in length (both 39-mers) and both carry a C20 fatty-diacid lipidation for extended in-vivo half-life in preclinical models. The sequence chimerism, however, differs: Tirzepatide draws primarily on GIP and GLP-1 features, while Retatrutide additionally incorporates sequence motifs from glucagon that enable GCGR agonism.
Both are common tool peptides in in-vitro receptor-pharmacology research. Neither is FDA-approved for any indication under BioInfinity supply; both are supplied strictly for laboratory research. The published literature focus for Tirzepatide is dual-receptor functional-selectivity between GLP-1R and GIPR; for Retatrutide it extends to triple-receptor functional-selectivity across GLP-1R / GIPR / GCGR.
Research Contexts in the Literature
Overlapping
- GLP-1R binding & activation assays
- GIPR pharmacology in-vitro
- cAMP signalling pathway research
- β-arrestin recruitment studies
- Preclinical rodent metabolic-model literature
- Peptide-lipidation & PK in-vitro research
- Chimeric-peptide design literature
Tirzepatide only
- Dual-agonist functional-selectivity between GLP-1R and GIPR
- Sequence features contributing to GIP potency vs GLP-1 potency
Retatrutide only
- GCGR (glucagon receptor) cross-reactivity studies
- Triple-agonist functional-selectivity across three receptor families
- Sequence features contributing to GCGR agonism in a chimeric backbone
All products supplied by BioInfinity are for in-vitro laboratory research use only. Not FDA-approved. Not intended for human or veterinary use. This page is a literature summary — not medical, dosing, or usage guidance.